TL;DR: The Centers for Medicare & Medicaid Services modified NCD 338 governing dermal injections for facial lipodystrophy syndrome, with a policy record date of January 9, 2026. Here's what billing teams need to know before submitting claims.
CMS dermal injection coverage policy under NCD 338 Medicare has been on the books since March 23, 2010, but this modified record is now live in the system as of January 9, 2026. The coverage criteria are narrow and specific: Medicare covers dermal injections for facial lipodystrophy syndrome (LDS) only when the filler is FDA-approved for this indication and the patient is HIV-positive with depression caused by antiretroviral treatment. No CPT or HCPCS codes are listed directly in this policy document — which creates its own set of billing challenges we'll cover below.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Dermal Injections for the Treatment of Facial Lipodystrophy Syndrome |
| Policy Code | NCD 338 |
| Change Type | Modified |
| Effective Date | January 9, 2026 (original coverage effective March 23, 2010) |
| Impact Level | Medium — narrow patient population, but high denial risk if criteria aren't met precisely |
| Specialties Affected | Infectious disease, dermatology, plastic surgery, HIV/AIDS specialty practices |
| Key Action | Confirm FDA approval status of the specific dermal filler used and document depression linked to antiretroviral treatment before submitting claims |
CMS Dermal Injections for Facial Lipodystrophy Coverage Criteria and Medical Necessity Requirements 2026
This coverage policy covers a very specific patient population. Understand the criteria cold before you bill a single claim.
Medicare covers dermal injections for facial LDS when three conditions are all true at the same time. The patient must be HIV-infected. The LDS must be caused by antiretroviral HIV treatment. And LDS must be a significant contributor to the patient's depression.
All three criteria must be present and documented. Miss any one of them and you're looking at a claim denial.
The filler itself also has to clear a separate bar. The Centers for Medicare & Medicaid Services requires the dermal filler to be FDA-approved specifically for the treatment of LDS — not just FDA-approved for dermal filling generally. This is a meaningful distinction. A filler approved for cosmetic wrinkle correction does not qualify here, even if a clinician uses it off-label for LDS.
The medical necessity standard here is tighter than most providers expect. The policy language says LDS must be "a significant contributor" to the patient's depression. That language needs to be reflected in your documentation. Vague chart notes won't hold up if a Medicare Administrative Contractor reviews the claim. Your documentation should directly connect the facial disfigurement caused by LDS to the patient's depressive symptoms.
The rationale behind this coverage policy is actually sound. Facial lipodystrophy — often severe facial wasting with sunken cheeks — is a documented side effect of long-term HAART. It can worsen depression and, more critically, cause patients to stop taking their antiretroviral medications. That non-adherence is a serious health outcome. CMS recognized that treating the physical appearance issue can improve both mental health and medication adherence. That's the clinical logic behind covering what would otherwise look like a cosmetic procedure.
Prior authorization requirements are not explicitly addressed in this NCD. That doesn't mean your MAC won't require it. Check your regional MAC's local coverage determination (LCD) policies before assuming prior auth isn't needed. Many MACs layer additional documentation requirements on top of NCDs.
Reimbursement for dermal injection procedures under this policy falls under the Physicians' Services benefit category. That placement matters for how claims route through the system.
CMS Dermal Injections for Facial Lipodystrophy Exclusions and Non-Covered Indications
The policy is explicit about two categories of non-covered services. Know both before your billing team touches a charge.
First: any dermal filler that does not carry FDA approval specifically for treating LDS is not covered. This is a firm exclusion. The FDA approval must be for this precise indication. Generic "dermal filler" approval status is not enough.
Second: dermal fillers used for any indication other than LDS in HIV-infected patients with antiretroviral-related depression are not covered. This means if a patient has HIV, has LDS, but does not have depression linked to their antiretroviral treatment, the injection is not covered. The depression component is not optional.
The real clinical exposure here is scope creep. A provider who treats multiple patients with HIV and facial wasting may be tempted to apply this coverage broadly. Don't. The coverage is tied to a specific causal chain — HAART causes LDS, LDS significantly contributes to depression. Every covered claim needs that full chain documented.
Cosmetic use of dermal fillers — even in HIV-positive patients — falls completely outside this policy. That's not a gray area.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Facial LDS caused by antiretroviral HIV treatment, with significant depression in HIV-infected beneficiary, using FDA-approved filler | Covered | No specific codes listed in NCD 338 | All three criteria must be documented: HIV+ status, HAART-caused LDS, depression significantly contributed to by LDS |
| Dermal fillers not FDA-approved for LDS treatment | Not Covered | N/A | FDA approval must be specific to LDS indication, not general dermal use |
| Dermal fillers used for any indication other than LDS in HIV-infected patients with antiretroviral-related depression | Not Covered | N/A | Includes cosmetic use, LDS without depression, and depression not linked to antiretroviral treatment |
CMS Dermal Injections Billing Guidelines and Action Items 2026
This policy's narrow criteria create specific billing risks. Here's what to do now.
| # | Action Item |
|---|---|
| 1 | Confirm FDA approval status for every filler your practice uses for LDS. Don't assume. Pull the FDA indication language for each product and verify it includes treatment of facial lipodystrophy syndrome specifically. If the filler isn't on that short list, the claim will not survive review. |
| 2 | Audit your clinical documentation templates before your next LDS billing cycle. Your chart notes need to document all three coverage elements explicitly: HIV-positive status, HAART as the cause of LDS, and LDS as a significant contributor to the patient's depression. A template that captures these three data points will protect you at audit. |
| 3 | Check with your MAC for prior authorization requirements and any applicable LCD. NCD 338 doesn't mandate prior auth, but your regional MAC may. Contact your MAC directly or check their LCD database. Don't skip this step — MAC-level requirements can get claims denied even when the NCD criteria are fully met. |
| 4 | Work with your coders to identify the correct HCPCS or CPT codes for the specific FDA-approved filler and injection procedure. NCD 338 does not list specific billing codes. Your coding team needs to identify the right codes based on the actual product used and the injection technique. Dermal injection billing varies by filler type and anatomical location — get this right before claims go out. |
| 5 | Flag this policy for your compliance officer if your practice bills dermal injections in any HIV specialty or infectious disease context. The line between covered and non-covered here is narrow enough that a compliance review is worth the time. If you're not sure how this applies to your patient mix, talk to your compliance officer before the effective date. |
| 6 | Train your front-end team to flag LDS patients during scheduling. Prior auth verification, documentation requirements, and filler confirmation all need to happen before the procedure. A pre-visit workflow catches problems before they become denials. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Dermal Injections for Facial Lipodystrophy Under NCD 338
Codes Listed in NCD 338
This policy does not list specific CPT, HCPCS, or ICD-10 codes. NCD 338 establishes coverage criteria only. Code selection depends on the specific FDA-approved dermal filler used and the injection procedure performed.
This is a real billing challenge. Your coding team needs to identify the right codes independently based on the product and procedure. Work with your coder or billing consultant to map your specific workflow to the correct HCPCS codes for the filler product and the correct procedure codes for the injection service.
What to Look For
When building your charge capture for LDS dermal injections, your team should look at:
- HCPCS codes for the specific FDA-approved dermal filler product (filler products often have product-specific J-codes or Q-codes)
- CPT or HCPCS procedure codes for the injection administration itself
- ICD-10-CM diagnosis codes that reflect HIV infection, lipodystrophy, and depression — all three diagnoses should appear on the claim to support medical necessity
Do not guess. If your billing team is uncertain which codes apply to the specific filler and procedure your practice uses, consult your MAC's billing guidance or a qualified billing consultant before submitting claims.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.